Trial · NCT02743221
Adverse events776
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 776
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 22 | 77 | 31 |
| other | Anaemia | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 5 | 76 | 7 |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 1 | 77 | 1 |
| other | Anaemia of chronic disease | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 1 | 76 | 1 |
| other | Anaemia of malignant disease | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 5 | 77 | 5 |
| other | Anaemia of malignant disease | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 1 | 76 | 2 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 1 | 77 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 0 | 76 | 0 |
| other | Haemolytic anaemia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 2 | 77 | 2 |
| other | Haemolytic anaemia | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 0 | 76 | 0 |
| other | Leukopenia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 6 | 77 | 9 |
| other | Leukopenia | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 2 | 76 | 5 |
| other | Neutropenia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 40 | 77 | 181 |
| other | Neutropenia | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 5 | 76 | 5 |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 1 | 77 | 1 |
| other | Spontaneous haematoma | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 1 | 76 | 1 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 11 | 77 | 22 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 4 | 76 | 5 |
| other | Thrombocytosis | Blood and lymphatic system disorders | Trifluridine/Tipiracil + Bevacizumab | 4 | 77 | 8 |
| other | Thrombocytosis | Blood and lymphatic system disorders | Capecitabine + Bevacizumab | 0 | 76 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02743221/events